(Date:11/24/2009)...ll/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglobalsp...tithassubmittedaMAAtotheEuropeanMedicinesAgencyfor...erapyindevelopment,forthetreatmentofType1Gaucherdi...ucerasealfathathasbeensubmitted,withprevious,submi...lobalsupplyshortageofthecurrentlyapprovedandmarket...
(Date:11/24/2009)...-FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX )toda...hairman,willpresentatthe21stAnnualPiperJaffrayHeal...009at10:00a.m.ET. ,, Toaccesstheliveandsubseque...torRelationssectionofGenomicHealth,swebsiteat http...ebsiteatleast15minutespriortothebeginningofthepres...
(Date:11/24/2009)...ustomers with Partners Validated to Process and An... , Ottawa, ON (PRWEB) Nove... of products for biological sample collection, sta...w global partner program. The program offers signi...unity and is designed to help partners scale and d...
(Date:11/24/2009)...--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTIC)man...hCareConference.TheconferencewillbeheldDecember1-2...tonTuesday,December1at11:00a.m.EasternTimeinHolmes...llbeavailableat www.celltherapeutics.com ,anditwil...rayHealthCareConference,NewYorkPalaceHotel,Holmes1...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3...Germany, August 1 , - Further Focus on Pharma & L...s business in technical plastic,systems. The busin...omponents for suppliers to the automobile industry...e science. For this purpose the sale process,has b...r bids., "Through the sale of the technical plast...
...if., July 31 Thermage, Inc.,(Nasdaq: THRM ), ann...sults,for the second quarter ended June 30, 2008, ... The Company will also host a conference call and,...Eastern Time (5:30 a.m.,Pacific) to discuss the fi.... The dial-in number for the conference call is 80...
...enue Grows 15 Percent Quarter-over-Quarter -, PAL...daq: CVTX ) today reported financial results for ...quarter ended June 30, 2008, the Company reported ...is compares to a net loss of $31.9,million, or $0...., 2008 and,$57.6 million, or $0.97 per share, for ...
Other Biology Technology:Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics 2CV Therapeutics Reports 2008 Second Quarter Financial Results 2CV Therapeutics Reports 2008 Second Quarter Financial Results 3CV Therapeutics Reports 2008 Second Quarter Financial Results 4CV Therapeutics Reports 2008 Second Quarter Financial Results 5CV Therapeutics Reports 2008 Second Quarter Financial Results 6CV Therapeutics Reports 2008 Second Quarter Financial Results 7...y which can immunocapture up to 50 g of Complex V ... bovine heart mitochondria for control immunocaptu...on of the ATP synthase complex (E.C. 3.6.3.14) fro...uent analysis of assembly state and activity. Thus...
Anti-11-keto Testosterone (EIA Antiserum) Antibody, Unconjugated from Cayman Chemical
Rabbit Anti-MKK6, phospho (Ser207) Polyclonal Antibody, Unconjugated from Abcam
Anti-Human L-Ficolin Monoclonal Antibody, Unconjugated, Clone GN4 from Cell Sciences
Biology Products: